- Market Capitalization, $K 140,325,280
- Shares Outstanding, K 2,624,374
- Annual Sales, $ 24,384 M
- Annual Income, $ 1,335 M
- 60-Month Beta 0.55
- Price/Sales 5.82
- Price/Cash Flow 17.08
- Price/Book 11.62
|Period||Period Low||Period High||Performance|
| || |
+1.61 (+3.06%)since 06/08/20
| || |
+10.34 (+23.58%)since 04/08/20
| || |
+13.36 (+32.72%)since 07/08/19
AstraZeneca (AZN) and Merck's Lynparza gets approval in the EU for treating patients with germline BRCA-mutated metastatic pancreatic cancer.
Shares of Corvus (CRVS) rise as it commences a phase I study to investigate a novel immunotherapy approach for patients with COVID-19.
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
Shares of Immunomedics (IMMU) rise after it announces positive phase III data for its breast-cancer drug, Trodelvy.
Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
, /PRNewswire/ -- The peptide therapeutics market is projected to grow with a CAGR of nearly 10.19% over the forecast period. The major factor attributing to the growth of the market is the growing incidence...
Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.
Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.
BMY vs. AZN: Which Stock Is the Better Value Option?
|United Kingdom Franklin FTSE ETF|
|Pharmaceutical Vaneck ETF|
|Advisorshares Dorsey Wright ADR|
|Advisorshares Doubleline Value Equity ETF|
|IQ 50% Hedged FTSE Europe|